Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
A quick intro to cash allocations in retirement portfolios. Understanding when to hold cash helps you balance liquidity with growth potential and manage market risk.
22,941 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
When a director sells shares after a sharp gain, it can spark questions about the stock’s future. This article breaks...
Two-thirds of the S&P 500 have reported, and the results are surprisingly strong. This could mean smoother gains for ...
The VanEck PFXF ETF focuses on non-financial preferred securities, offering a ~6.7% yield. But investors must watch c...
Nvidia's surge in AI chips is reshaping markets, and some analysts frame it as a $200 billion warning for rivals like...
A year ago, the idea that AI could tame inflation sounded compelling. Today, the same tech may be adding price pressu...
A Franklin Electric insider sold 1,900 shares for about $190k, prompting questions about FELE. This guide explains in...
AMD stock soared in May as AI-driven demand, data center expansion, and a refreshed product lineup converged to lift ...
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
A major federal loan initiative aims to revitalize nuclear power by backing five new projects with $17.5 billion. Thi...
When a Lincoln Educational director sold a sizable block of shares, investors took note. This article breaks down the...
Oklo has zigzagged from a peak near $193 to much lower levels, raising questions about its momentum and prospects. Th...